(73) This preclinical rationale for JAK-STAT inhibition has been translated to the clinical setting with several case reports noting resolution of refractory CRS after treatment with the JAK-inhibitor ruxolitinib. This evidence concerns the gene SOAT1 and congenital rubella syndrome.